Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials

By afschroeder • September 22, 2025

Gold LS, Armstrong AW, Bissonnette R, Magnolo N, Vender RB, Sebastian M, Galimberti ML, Tsianakas A, Arnone M, Wallace P, Simon M, Riera-Monroig J, Gerdes S, Waibel J, Gonzalez-Cantero A, Schwarz B, Tada Y, Cecchini M, Ehst B, Kircik L, Kephart L, Reyes-Servin O, Edem BE, Campbell JH, Shen YK, Cresswell K, Li S, DeKlotz CMC, Nunes F, Papp KA. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025 Sep 18:S0140-6736(25)01576-4. doi: 10.1016/S0140-6736(25)01576-4. Epub ahead of print. PMID: 40976249.

Tags: Dermatology, Publications

Novel Taxol-Derivative, STO-1, Induces Selective Anti-Tumor Immunity and Sustained Remission of Glioblastoma Without Triggering Autoimmune Reactions

Mohapatra S, Guerrero A, Rahman N, Zaman KT, Wu J, Onyeagba C, Hu C, Pellegrini M, Vankudoth J, Kitamura S, O'Donnell L, Wadghiri YZ, Banerjee[...]

Library Preparation for Genome-Wide DNA Methylation Profiling

Hsu FM, Pellegrini M, Chen PY. Library Preparation for Genome-Wide DNA Methylation Profiling. Bio Protoc. 2025 Nov 5;15(21):e5488. doi: 10.21769/BioProtoc.5488. PMID: 41220974; PMCID: PMC12602117.

Cutaneous metastases of alveolar rhabdomyosarcoma in a young adult

Yan MJ, Wongvibulsin S, McKenzie S, Smart CN, Nguyen MO. Cutaneous metastases of alveolar rhabdomyosarcoma in a young adult. JAAD Case Rep. 2025 Sep 26;66:23-25.[...]